Close Menu

NEW YORK – Adaptive Biotechnologies reported after the close of the market on Wednesday that its fourth quarter revenues increased 25 percent year over year, driven by development revenues.

For the three months ended Dec. 31, 2020, the Seattle-based immune sequencing firm tallied revenues of $30.2 million, compared to $24.2 million a year ago, and above analysts' average estimate of $26.9 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.